Suven Life Sciences Limited

SUVEN

INE495B01038

Biotechnology & Medical Research

Delayed Bombay S.E. Other stock markets 05:56:38 27/05/2024 BST			5-day change	1st Jan Change
98.5 ^INR	-1.35%		-0.76%	+22.12%

05-06	Suven Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
05-06	Suven Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Suven Life Sciences Limited Appoints D.G. Prasad to its Board

June 18, 2020 at 10:17 am

Suven Life Sciences Limited approved appointment of Independent Director D.G. Prasad on the Board of WOS (i.e., Suven Pharma Inc.).

Latest news about Suven Life Sciences Limited

Suven Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-06	CI
Suven Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-06	CI
Suven Life Sciences to Present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology 2024 Annual Meeting, Denver, USA	04-15	CI
Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder Study in USA	02-06	CI
Suven Life Sciences Limited Approves the Retirement of Gopalakrishna Muddusetty as Non-Executive Independent Director, Effective March 31, 2024	01-30	CI
Suven Life Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	01-30	CI
Suven Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-04	CI
Suven Life Sciences Announces Positive Topline Results from A Phase-2 Study Evaluating Samelisant (SUVN-G3031) for Excessive Daytime Sleepiness in Adult Narcolepsy Patients with and Without Cataplexy	30/10/23	CI
Suven Pharma Appoints New Board and Management Team	29/09/23	CI
Suven Pharma Appoints Sudhir Kumar Singh as CEO	29/09/23	CI
Transcript : Suven Life Sciences Limited, Q1 2024 Earnings Call, Aug 10, 2023	10/08/23
Suven Life Sciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	08/08/23	CI
Suven Life Sciences Completes Enrollment of Patients to the Phase-2, Proof of Concept Clinical Study of Samelisant (SUVN-G3031) for the Treatment of Narcolepsy with or Without Cataplexy in USA and Canada	01/06/23	CI
Transcript : Suven Life Sciences Limited, Q4 2023 Earnings Call, May 26, 2023	25/05/23
Suven Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2023	09/05/23	CI
Suven Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	09/05/23	CI
Li & Fung considers options for $500 mln Asia healthcare arm, including a sale - sources	16/01/23	RE
Suven Life Sciences Limited Announces the Randomization of First Patient in the Phase-3 Global Clinical Trial of Masupirdine for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type	16/11/22	CI
Suven Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	10/11/22	CI
Transcript : Suven Life Sciences Limited, Q2 2023 Earnings Call, Nov 09, 2022	09/11/22
Suven Pharmaceuticals' Consolidated Net Profit Declines in Fiscal Q2	08/11/22	MT
Suven Life Sciences Gets Board Panel Nod for Rights Issue	14/10/22	MT
Suven Pharmaceuticals Board Declares Interim Dividend and Special Dividend for Fiscal 2023	02/09/22	MT
Suven Life Sciences Limited Declares Special Dividend for the Financial Year 2022-23, Payable on and from September 20, 2022	02/09/22	CI
Suven Pharmaceuticals Mulls Interim Dividend for Fiscal 2023	29/08/22	MT

Chart Suven Life Sciences Limited

Duration

Period

More charts

Suven Life Sciences Limited is an India-based biopharmaceutical company. The Company is engaged in the drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. It operates through the research and development services segment. Its drug discovery & research/clinical pipeline include Masupirdine (SUVN-502) Neuropsychiatric Symptoms in Alzheimer's, Masupirdine (SUVN-502) Cognitive deficits in AD, Samelisant (SUVN-G3031) Narcolepsy, Samelisant (SUVN-G3031) Cognitive Disorders, Ropanicant (SUVN-911) Depressive Disorders, Usmarapride (SUVN-D4010), Cognitive Disorders, SUVN-I6107, Cognitive Disorders and Schizophrenia, SUVN-M8036, Psychiatric Disorders, and SUVN-D1044 Gastrointestinal Disorders. Its drug discovery & development support services (DDDSS) include synthetic and medicinal chemistry, analytical chemistry, in vitro biology, ADME, pharmacology, toxicology, bioanalysis, and NCE formulations.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SUVEN LIFE SCIENCES LIMITED	+22.12%	262M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research